分析:药物类别对抗高血压药物的坚持的影响
Ian M Kronish1, Mark Woodward, Ziad Sergie
1Division of General Internal Medicine, Mount Sinai School of Medicine, New York, NY, USA. ian.kronish@mssm.edu
Circulation
|April 6, 2011
概括
患者对血压药物的坚持因药物类别而异. 抗胰岛素II受体阻断剂的坚持率最高,而利尿剂和β-阻断剂的坚持率最低,尽管整体坚持率仍然不够理想.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 心血管医学 心血管医学
背景情况:
- 观察性研究表明,不同的抗高血压药物类别的坚持率各不相同.
- 在临床实践中,量化抗高血压药物类别与患者坚持治疗之间的关联至关重要.
研究的目的:
- 系统地评估和量化各种抗高血压药物类别的坚持差异.
- 确定哪些抗高血压药物类与更好或更差的患者坚持相关.
主要方法:
- 在2009年2月1日之前,对英语文章进行系统的文献搜索.
- 包括通过药物补充数据测量抗高血压药物坚持的研究.
- 使用反变量加权随机效应模型进行元分析,以组合危险比率.
主要成果:
- 聚合的平均坚持率从β抑制剂的28%到血管新生素II受体抑制剂的65%.
- 与ACE抑制剂,CCBs,利尿剂和β-阻断剂相比,血管新生素II受体阻断剂的坚持性更高.
- 考虑到出版偏差后,在某些药物类别的比较中不再观察到坚持的显著差异.
结论:
- 在临床环境中,在不同药物类别中,抗高血压药物的坚持存在显著差异.
- 利尿剂和β抑制剂表现出最低的坚持率,而血管新素II受体抑制剂和ACE抑制剂显示出最高的坚持率.
- 在所有研究的抗高血压药物类别中,整体药物坚持率低于最佳.
相关概念视频
Antihypertensive Drugs: Action of β1 Blockers
2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Direct Renin Inhibitors
1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Hypertension IV: Drug Therapy and Lifestyle Modifications
1.0K
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
1.0K


